7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 
      
    		                                                               
      cash flows from operating activities:
    		                                                               
      net earnings/
    		2,195,000,000 1,313,000,000 2,462,000,000               1,061,000,000 2,029,000,000                                             
      adjustments to reconcile net earnings/(loss) to net cash from operating activities:
    		                                                               
      depreciation and amortization
    		1,011,000,000 1,011,000,000 1,012,000,000 1,880,000,000 2,592,000,000 2,596,000,000 2,532,000,000 2,464,000,000 2,435,000,000 2,432,000,000 2,429,000,000 2,521,000,000 2,588,000,000 2,583,000,000 2,584,000,000 2,579,000,000 2,727,000,000 2,712,000,000 2,668,000,000 2,690,000,000 2,655,000,000 2,558,000,000 2,477,000,000 1,236,000,000 171,000,000 169,000,000 170,000,000 172,000,000 165,000,000 157,000,000 143,000,000 197,000,000 188,000,000 211,000,000 193,000,000 122,000,000 105,000,000 90,000,000 65,000,000 76,000,000 105,000,000 91,000,000 104,000,000 103,000,000 112,000,000 115,000,000 137,000,000 181,000,000 180,000,000 189,000,000 213,000,000 199,000,000            
      deferred income taxes
    		-359,000,000 -437,000,000 223,000,000 -791,000,000 -256,000,000 -331,000,000 -711,000,000 -1,327,000,000 -327,000,000 -1,086,000,000 -548,000,000 -624,000,000 -645,000,000 -782,000,000 -687,000,000 -1,266,000,000 -32,000,000 -163,000,000 68,000,000 -436,000,000 54,000,000 1,418,000,000 -53,000,000 -337,000,000 -500,000,000 -89,000,000 2,000,000 247,000,000 -124,000,000 -197,000,000 160,000,000 727,000,000 262,000,000 91,000,000 -70,000,000 296,000,000 -183,000,000 -71,000,000 -246,000,000 -398,000,000 110,000,000 -52,000,000 -7,000,000 -485,000,000 -93,000,000 -74,000,000 110,000,000 -82,000,000 -74,000,000 -153,000,000 -182,000,000 -493,000,000         3,000,000 7,000,000 90,000,000 
      stock-based compensation
    		139,000,000 137,000,000 144,000,000 120,000,000 129,000,000 125,000,000 133,000,000 127,000,000 132,000,000 137,000,000 122,000,000 119,000,000 115,000,000 116,000,000 107,000,000 133,000,000 142,000,000 157,000,000 151,000,000 171,000,000 185,000,000 213,000,000 210,000,000 284,000,000 56,000,000 48,000,000 53,000,000 53,000,000 62,000,000 51,000,000 55,000,000 50,000,000 50,000,000 54,000,000 45,000,000 56,000,000 48,000,000 54,000,000 47,000,000 59,000,000 63,000,000 59,000,000 54,000,000 66,000,000 48,000,000 50,000,000 49,000,000 51,000,000 45,000,000 46,000,000 49,000,000 46,000,000         47,000,000 49,000,000 47,000,000 
      impairment charges
    		196,000,000   1,953,000,000 139,000,000 870,000,000 1,000,000 29,000,000 159,000,000 47,000,000 20,000,000 35,000,000 61,000,000 42,000,000 41,000,000 15,000,000 613,000,000 240,000,000 339,000,000 1,072,000,000 15,000,000 63,000,000 53,000,000 16,000,000 9,000,000 129,000,000 45,000,000 16,000,000 6,000,000 24,000,000 80,000,000 109,000,000 4,000,000 141,000,000 78,000,000 33,000,000 7,000,000 49,000,000 19,000,000 168,000,000 4,000,000 7,000,000 13,000,000 15,000,000 28,000,000 311,000,000 47,000,000 34,000,000 2,000,000 1,000,000 3,000,000 62,000,000 1,830,000,000 192,000,000 96,000,000 0 13,000,000 0 15,000,000     
      divestiture gains and royalties
    		-295,000,000 -293,000,000 -292,000,000 -281,000,000 -288,000,000 -270,000,000 -280,000,000 -245,000,000 -222,000,000 -223,000,000 -194,000,000 -243,000,000 -208,000,000 -225,000,000 -387,000,000 -222,000,000 -160,000,000 -167,000,000 -135,000,000 -213,000,000 -191,000,000 -122,000,000 -173,000,000 -179,000,000 -1,356,000,000 -154,000,000 -166,000,000 -170,000,000 -325,000,000 -242,000,000 -255,000,000 -160,000,000 -135,000,000 -135,000,000 -276,000,000 -105,000,000 -155,000,000 -420,000,000 -507,000,000                         
      acquired iprd
    		633,000,000 1,507,000,000 188,000,000 30,000,000 262,000,000 132,000,000 12,949,000,000 600,000,000 80,000,000 158,000,000 75,000,000 52,000,000 30,000,000 400,000,000 333,000,000                                                 
      equity investment (gains)/losses
    		-190,000,000 22,000,000 78,000,000 205,000,000 -12,000,000 -107,000,000 -102,000,000            -601,000,000 -504,000,000                                            
      contingent consideration fair value adjustments
    		0           -10,000,000 0 0 1,000,000 -32,000,000 0 0 -510,000,000 -1,160,000,000 -988,000,000 -165,000,000 556,000,000                                         
      other adjustments
    		-74,000,000 -12,000,000 10,000,000 -29,000,000 103,000,000 -2,000,000 22,000,000 48,000,000 269,000,000 -13,000,000 4,000,000 54,000,000 -40,000,000 -30,000,000 248,000,000 -26,000,000 -36,000,000 -29,000,000 233,000,000 -37,000,000 -48,000,000 -50,000,000 -42,000,000 -1,000,000 -7,000,000 -8,000,000 -6,000,000 -1,000,000 -16,000,000 2,000,000 -29,000,000 -16,000,000 9,000,000 66,000,000 33,000,000 12,000,000 -32,000,000 -14,000,000 -10,000,000 288,000,000 -365,000,000                       
      changes in operating assets and liabilities:
    		                                                               
      receivables
    		155,000,000 -484,000,000 15,000,000 143,000,000 661,000,000 -1,019,000,000 479,000,000 -508,000,000 -247,000,000 -65,000,000 -175,000,000 -106,000,000 -674,000,000 -669,000,000 786,000,000 -168,000,000 -260,000,000 -693,000,000 67,000,000 -290,000,000 -159,000,000 546,000,000 -743,000,000 318,000,000 127,000,000 71,000,000 236,000,000 -207,000,000 -334,000,000 -107,000,000 219,000,000 108,000,000 -85,000,000 -208,000,000 -246,000,000 93,000,000 -44,000,000 -428,000,000 -424,000,000 -356,000,000 -319,000,000 -176,000,000 -91,000,000 -186,000,000 -35,000,000 24,000,000 -55,000,000 59,000,000 -159,000,000 -86,000,000 -318,000,000 5,000,000 99,000,000 652,000,000 -108,000,000 -68,000,000 176,000,000 -237,000,000 -91,000,000 -148,000,000 -68,000,000 255,000,000 -309,000,000 
      inventories
    		-90,000,000 4,000,000 -169,000,000 175,000,000 -218,000,000 -225,000,000 -218,000,000 -197,000,000 -256,000,000 -16,000,000 -282,000,000 -41,000,000 -16,000,000 -13,000,000 1,000,000 -128,000,000 30,000,000 5,000,000 106,000,000 101,000,000 481,000,000 642,000,000 1,448,000,000 470,000,000 -35,000,000 -7,000,000 35,000,000 -64,000,000 -30,000,000 -118,000,000 -4,000,000 -36,000,000 65,000,000 13,000,000 -71,000,000 -45,000,000 4,000,000 -67,000,000 -44,000,000 -134,000,000 69,000,000 111,000,000 51,000,000 -92,000,000 -5,000,000 -13,000,000 -144,000,000 -37,000,000 165,000,000 -10,000,000 -163,000,000 32,000,000 35,000,000 -102,000,000 -68,000,000 -43,000,000 96,000,000 -162,000,000 -84,000,000 193,000,000 -49,000,000 -13,000,000 25,000,000 
      accounts payable
    		160,000,000 13,000,000 -85,000,000 517,000,000 -374,000,000 -259,000,000 300,000,000 444,000,000 -268,000,000 -165,000,000 187,000,000 405,000,000 -300,000,000 -19,000,000 23,000,000 226,000,000 -139,000,000 -145,000,000 303,000,000 132,000,000 -424,000,000 -223,000,000 703,000,000 181,000,000 -108,000,000 20,000,000 136,000,000 127,000,000 -85,000,000 140,000,000 -241,000,000 257,000,000 148,000,000 29,000,000 -114,000,000 246,000,000 -106,000,000 41,000,000 -77,000,000 299,000,000 -600,000,000 -535,000,000 -83,000,000 -107,000,000 175,000,000 -100,000,000 -12,000,000 111,000,000 98,000,000 256,000,000 -53,000,000 89,000,000 -99,000,000 -254,000,000 32,000,000 284,000,000 -103,000,000 350,000,000 62,000,000 238,000,000 23,000,000 -65,000,000 119,000,000 
      rebates and discounts
    		1,703,000,000 881,000,000 -627,000,000 -405,000,000 1,819,000,000 735,000,000 -665,000,000 -211,000,000 1,533,000,000 492,000,000 -910,000,000 -303,000,000 1,140,000,000 520,000,000 -930,000,000                                                 
      income taxes payable
    		887,000,000 -621,000,000 54,000,000 121,000,000 -348,000,000 -1,943,000,000 910,000,000 1,044,000,000 -412,000,000 -2,119,000,000 884,000,000 -1,113,000,000 60,000,000 -1,201,000,000 831,000,000 -222,000,000 -46,000,000 -1,022,000,000 227,000,000 -201,000,000 -2,289,000,000 -44,000,000 229,000,000 860,000,000 112,000,000 -261,000,000 196,000,000 -37,000,000 -17,000,000 102,000,000 114,000,000 2,197,000,000 -65,000,000 51,000,000 414,000,000 -283,000,000 253,000,000 -520,000,000 5,000,000 -30,000,000 53,000,000 -57,000,000 81,000,000 89,000,000 273,000,000 24,000,000 -215,000,000 -2,000,000 159,000,000               
      other
    		240,000,000 222,000,000 -1,059,000,000 725,000,000 167,000,000 340,000,000 -608,000,000 283,000,000 -59,000,000 173,000,000 -1,064,000,000 700,000,000 -46,000,000 -191,000,000 -1,073,000,000 -627,000,000 1,065,000,000 442,000,000 -1,137,000,000 104,000,000 1,105,000,000 220,000,000 -355,000,000 17,000,000 899,000,000 718,000,000 -932,000,000 826,000,000 129,000,000 374,000,000 -695,000,000 226,000,000 154,000,000 170,000,000 -777,000,000 567,000,000 29,000,000 298,000,000 -794,000,000    -832,000,000 -17,000,000 102,000,000 96,000,000 -214,000,000 2,000,000 0 -8,000,000 -3,000,000 -56,000,000 8,000,000 3,000,000 10,000,000 80,000,000 -25,000,000 -2,000,000 -111,000,000     
      net cash provided by/(used in) operating activities
    		                                  861,000,000            617,000,000    -428,000,000             
      cash flows from investing activities:
    		                                                               
      sale and maturities of marketable debt securities
    		829,000,000 524,000,000 220,000,000 62,000,000 238,000,000 75,000,000 747,000,000 41,000,000 365,000,000 270,000,000 57,000,000 1,206,000,000 1,417,000,000 1,688,000,000 2,100,000,000 1,244,000,000 984,000,000 1,186,000,000 782,000,000 1,523,000,000 1,220,000,000 2,143,000,000 1,394,000,000                                         
      purchase of marketable debt securities
    		-665,000,000 -621,000,000 -636,000,000 -371,000,000 -40,000,000 -84,000,000 -274,000,000 -717,000,000 -502,000,000 -355,000,000 -200,000,000 -26,000,000 -274,000,000 -1,578,000,000 -1,714,000,000 -2,070,000,000 -1,065,000,000 -1,041,000,000 -1,302,000,000 -1,024,000,000 -1,191,000,000 -1,222,000,000 -735,000,000                                         
      proceeds from sales of equity investments
    		49,000,000 0 12,000,000 205,000,000 0 55,000,000 5,000,000                                                         
      capital expenditures
    		-320,000,000 -361,000,000 -260,000,000 -378,000,000 -324,000,000 -262,000,000 -284,000,000 -330,000,000 -342,000,000 -259,000,000 -278,000,000 -346,000,000 -247,000,000 -272,000,000 -253,000,000 -320,000,000 -270,000,000 -210,000,000 -173,000,000 -283,000,000 -153,000,000 -131,000,000 -186,000,000 -251,000,000 -190,000,000 -191,000,000 -204,000,000 -290,000,000 -224,000,000 -198,000,000 -239,000,000 -254,000,000 -262,000,000 -248,000,000 -291,000,000 -371,000,000 -341,000,000 -261,000,000 -242,000,000                         
      free cash flows
    		 3,556,000,000 1,694,000,000 4,061,000,000 5,267,000,000 2,064,000,000 2,550,000,000 3,922,000,000 4,409,000,000 1,628,000,000 2,692,000,000 2,960,000,000 3,440,000,000 1,989,000,000 3,559,000,000 3,737,000,000 4,996,000,000 2,850,000,000 3,651,000,000 3,387,000,000 2,066,000,000 4,138,000,000 3,708,000,000 1,787,000,000 2,366,000,000 1,892,000,000 1,186,000,000 2,139,000,000 1,055,000,000 859,000,000 936,000,000 863,000,000 1,451,000,000   1,057,000,000 1,056,000,000                           
      divestiture and other proceeds
    		279,000,000 270,000,000 243,000,000 333,000,000 255,000,000 270,000,000 241,000,000 241,000,000 247,000,000 194,000,000 227,000,000 490,000,000 221,000,000 192,000,000 402,000,000 178,000,000 188,000,000 -203,000,000 585,000,000 320,000,000 202,000,000 143,000,000 205,000,000 13,765,000,000 1,719,000,000 197,000,000 171,000,000 302,000,000 364,000,000 208,000,000 375,000,000 196,000,000 137,000,000 148,000,000 241,000,000 141,000,000 190,000,000 564,000,000 439,000,000                         
      acquisition and other payments, net of cash acquired
    		-1,874,000,000 -285,000,000 -78,000,000 -47,000,000 -348,000,000 -1,373,000,000 -20,053,000,000 -581,000,000 -326,000,000 -184,000,000 -78,000,000 -116,000,000 -3,261,000,000 -467,000,000 -442,000,000 -152,000,000 -1,057,000,000 -366,000,000 -35,000,000 -12,663,000,000 -243,000,000 -153,000,000 -25,000,000                                         
      net cash provided by/(used in) investing activities
    		              95,000,000          491,000,000 715,000,000 1,060,000,000     1,019,000,000 142,000,000 -1,024,000,000 -203,000,000 16,000,000 -368,000,000   -984,000,000 -62,000,000   351,000,000      57,000,000 161,000,000             
      cash flows from financing activities:
    		                                                               
      proceeds from issuance of short-term debt obligations
    		   0 0                                                           
      repayments of short-term debt obligations
    		   0 -269,000,000                                                           
      other short-term financing obligations
    		5,000,000 58,000,000 368,000,000 -405,000,000 95,000,000                                                           
      proceeds from issuance of long-term debt
    		   0 0                                           1,477,000,000 0 0 12,000,000 0            
      repayments of long-term debt
    		-229,000,000   0 -2,478,000,000                                    0   0 0 0 -676,000,000                 
      dividends
    		-1,263,000,000 -1,262,000,000 -1,258,000,000 -1,218,000,000 -1,216,000,000 -1,217,000,000 -1,212,000,000 -1,160,000,000 -1,191,000,000 -1,197,000,000 -1,196,000,000 -1,145,000,000 -1,154,000,000 -1,150,000,000 -1,185,000,000 -1,099,000,000 -1,090,000,000 -1,099,000,000 -1,108,000,000 -1,021,000,000 -1,016,000,000 -1,021,000,000 -1,017,000,000 -668,000,000 -671,000,000 -671,000,000 -669,000,000 -653,000,000 -653,000,000 -654,000,000 -653,000,000 -639,000,000 -640,000,000 -643,000,000 -655,000,000 -635,000,000 -636,000,000 -635,000,000 -641,000,000 -618,000,000 -617,000,000 -619,000,000 -623,000,000 -598,000,000 -597,000,000 -598,000,000 -605,000,000 -577,000,000 -577,000,000               
      stock option proceeds and other
    		-3,000,000 11,000,000 -103,000,000 -19,000,000 16,000,000 -6,000,000 -97,000,000 25,000,000 41,000,000 53,000,000 -92,000,000                                                     
      net cash provided by/(used in) financing activities
    		   -1,642,000,000 -3,852,000,000 -4,023,000,000 14,644,000,000                 -7,677,000,000 -941,000,000                                       
      effect of exchange rates on cash, cash equivalents and restricted cash
    		-4,000,000 128,000,000 66,000,000 -147,000,000 77,000,000 -22,000,000 -45,000,000 78,000,000 -38,000,000 -8,000,000 13,000,000 95,000,000 -66,000,000 -71,000,000 9,000,000 -54,000,000 -28,000,000 18,000,000 -38,000,000 87,000,000 31,000,000 60,000,000 -67,000,000                                         
      increase/(decrease) in cash, cash equivalents and restricted cash
    		3,115,000,000 1,736,000,000 528,000,000                                                             
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 10,347,000,000 0 0 0 11,519,000,000  0 0 9,325,000,000  0 0 14,316,000,000  0 0 14,973,000,000  0 0 12,820,000,000                                         
      cash, cash equivalents and restricted cash at end of period
    		3,115,000,000 1,736,000,000 10,875,000,000 2,454,000,000 1,597,000,000 -3,038,000,000 9,334,000,000  -857,000,000 -623,000,000 9,048,000,000  -3,003,000,000 -1,619,000,000 12,579,000,000  2,482,000,000 76,000,000 11,321,000,000  -502,000,000 4,116,000,000 16,246,000,000                                         
      net cash from operating activities
    		 3,917,000,000 1,954,000,000 4,439,000,000 5,591,000,000 2,326,000,000 2,834,000,000 4,252,000,000 4,751,000,000 1,887,000,000 2,970,000,000 3,306,000,000 3,687,000,000 2,261,000,000 3,812,000,000 4,057,000,000 5,266,000,000 3,060,000,000 3,824,000,000 3,670,000,000 2,219,000,000 4,269,000,000 3,894,000,000 2,038,000,000 2,556,000,000 2,083,000,000 1,390,000,000 2,429,000,000 1,279,000,000 1,057,000,000 1,175,000,000 1,117,000,000 1,713,000,000   1,428,000,000 1,397,000,000   611,000,000 524,000,000 71,000,000 626,000,000 572,000,000 903,000,000   1,410,000,000 1,053,000,000   836,000,000 4,584,000,000 1,134,000,000 387,000,000 1,568,000,000 1,698,000,000 1,093,000,000 481,000,000 1,595,000,000 1,383,000,000 1,049,000,000 464,000,000 
      net cash from investing activities
    		 -473,000,000 -499,000,000 -196,000,000 -219,000,000 -1,319,000,000 -19,618,000,000 -1,346,000,000 -410,000,000   1,213,000,000        -12,127,000,000 -165,000,000 780,000,000 653,000,000      -147,000,000 -348,000,000 -43,000,000        1,426,000,000    754,000,000   -1,511,000,000 2,212,000,000 -315,000,000    277,000,000 -4,203,000,000 226,000,000 -3,027,000,000 495,000,000 -163,000,000 -332,000,000 -1,437,000,000  948,000,000 238,000,000 -2,519,000,000 
      net cash (used in)/provided by financing activities
    		 -1,836,000,000 -993,000,000                 3,483,000,000 -2,587,000,000                                         -495,000,000 -486,000,000 
      net (loss)/earnings
    		   76,000,000 1,215,000,000 1,684,000,000 -11,908,000,000               -80,000,000 -766,000,000                                         
      adjustments to reconcile net (loss)/earnings to net cash from operating activities:
    		                                                               
      repurchase of common stock
    		       0 -4,000,000,000 -905,000,000 -250,000,000 -2,416,000,000 -585,000,000 0 -5,000,000,000 -2,751,000,000 -525,000,000 -1,236,000,000 -1,775,000,000 -1,465,000,000 0 0 -81,000,000 -7,000,000,000    0 0 -153,000,000 -167,000,000 -249,000,000 -220,000,000 0 -2,000,000,000 0 0 0 -231,000,000                         
      (decrease)/increase in cash, cash equivalents and restricted cash
    		                2,482,000,000 76,000,000 -3,652,000,000                                             
      adjustments to reconcile net earnings to net cash from operating activities:
    		                                                               
      decrease in cash, cash equivalents and restricted cash
    		    1,597,000,000 -3,038,000,000 -2,185,000,000  -857,000,000 -623,000,000 -277,000,000  -3,003,000,000 -1,619,000,000 -1,737,000,000                                                 
      short-term debt obligations
    		      3,070,000,000 -353,000,000 -10,000,000 115,000,000 128,000,000 136,000,000 -72,000,000 88,000,000 42,000,000 -114,000,000 139,000,000 -123,000,000 -62,000,000 -3,000,000 -242,000,000 -48,000,000 26,000,000 16,000,000 31,000,000 157,000,000 -73,000,000 74,000,000 -71,000,000 -202,000,000 -344,000,000 -471,000,000 898,000,000                               
      issuance of long-term debt
    		      12,883,000,000     0 0 0 5,926,000,000         7,988,000,000 0       0 0 0 1,488,000,000     0 0                       
      repayment of long-term debt
    		       -2,000,000,000 0 -239,000,000 -1,640,000,000 0 -2,785,000,000 -2,877,000,000 -5,769,000,000 0 -500,000,000 -1,000,000,000 -4,522,000,000 -1,250,000,000    -8,000,000,000 0 -6,000,000 -1,250,000,000 0 0   0 -750,000,000                               
      net earnings
    		       1,762,000,000 1,934,000,000 2,077,000,000 2,267,000,000  1,608,000,000 1,429,000,000 1,283,000,000         -1,060,000,000 1,366,000,000 1,439,000,000 1,715,000,000 1,158,000,000 1,912,000,000 382,000,000 1,495,000,000 -2,329,000,000 856,000,000 922,000,000 1,526,000,000 898,000,000 1,215,000,000 1,188,000,000 1,206,000,000 -188,000,000 730,000,000 -110,000,000 1,199,000,000 27,000,000 732,000,000 334,000,000 936,000,000 735,000,000 692,000,000 530,000,000 623,000,000 924,000,000 -713,000,000 808,000,000 1,482,000,000 1,231,000,000 1,355,000,000 1,307,000,000 1,367,000,000 842,000,000 1,302,000,000 1,268,000,000 1,101,000,000 
      equity investment losses/(gains)
    		                                                               
      proceeds from sales of equity investment securities
    		         5,000,000 62,000,000 5,000,000 63,000,000 148,000,000 2,000,000 1,521,000,000 244,000,000                                               
      net cash from financing activities
    		       967,000,000 -5,160,000,000 -2,173,000,000 -3,050,000,000 -3,246,000,000 -4,543,000,000 -3,520,000,000 -5,653,000,000  -1,780,000,000 -3,182,000,000 -7,295,000,000    -1,054,000,000    -2,029,000,000 -578,000,000 -720,000,000 -1,015,000,000 -1,222,000,000 -1,352,000,000 -706,000,000 -1,006,000,000 -1,013,000,000 -590,000,000 -539,000,000 -524,000,000 -792,000,000 -1,086,000,000 -700,000,000 -883,000,000 -682,000,000 -231,000,000 -528,000,000 -486,000,000 -1,192,000,000 711,000,000 -620,000,000 -1,115,000,000 -44,000,000 -958,000,000 -1,689,000,000 -850,000,000 -836,000,000 -754,000,000 -704,000,000 -507,000,000 -692,000,000 -1,664,000,000    
      cash, cash equivalents and restricted cash at beginning of year
    		                                                               
      cash, cash equivalents and restricted cash at end of year
    		                                                               
      equity investment losses
    		        0 58,000,000 155,000,000                                                     
      net cash (used in)/provided by investing activities
    		          -210,000,000        -143,000,000                                             
      equity investment losses/
    		            14,000,000 308,000,000 644,000,000        339,000,000                                         
      pension settlements and amortization
    		              7,000,000 5,000,000 5,000,000 14,000,000 11,000,000 9,000,000 12,000,000 11,000,000 11,000,000 5,000,000 1,557,000,000 60,000,000 66,000,000 41,000,000 41,000,000 54,000,000 50,000,000 88,000,000 41,000,000 55,000,000 52,000,000 47,000,000 39,000,000 44,000,000 39,000,000 67,000,000 68,000,000 60,000,000 50,000,000                     
      iprd charge - myokardia acquisition
    		                                                               
      asset acquisition charges
    		               86,000,000 270,000,000 796,000,000 5,000,000 821,000,000 178,000,000   0 0   0 0 25,000,000 60,000,000 250,000,000 310,000,000   0 35,000,000 139,000,000 100,000,000                         
      equity investment gains
    		               469,000,000 -465,000,000          -175,000,000                                     
      increase in cash, cash equivalents and restricted cash
    		                   -4,887,000,000 -502,000,000 4,116,000,000 3,426,000,000                                         
      deferred income
    		                       -1,000,000 4,000,000 -6,000,000 15,000,000 0 -8,000,000 69,000,000 23,000,000 -551,000,000 -89,000,000 -76,000,000 74,000,000 -509,000,000 182,000,000 28,000,000 235,000,000 65,000,000 325,000,000 -506,000,000 334,000,000 209,000,000 -19,000,000 96,000,000 327,000,000 263,000,000 83,000,000 404,000,000 215,000,000   43,000,000 -91,000,000 4,000,000 -21,000,000 -41,000,000 -57,000,000 116,000,000 -8,000,000 -26,000,000 35,000,000 
      sale and maturities of marketable securities
    		                        176,000,000 938,000,000 1,350,000,000 926,000,000 373,000,000 638,000,000 442,000,000 2,116,000,000 2,013,000,000 1,120,000,000 1,163,000,000 1,135,000,000 880,000,000 1,034,000,000 1,760,000,000 345,000,000 641,000,000        242,000,000    1,047,000,000 1,147,000,000 2,190,000,000         
      purchase of marketable securities
    		                        -1,205,000,000 -195,000,000 -242,000,000 -1,243,000,000 -615,000,000 -162,000,000 -285,000,000 -1,003,000,000 -1,393,000,000 -1,837,000,000 -1,204,000,000 -841,000,000 -1,053,000,000 -672,000,000 -523,000,000                         
      acquisition and other payments
    		                        -9,000,000 -34,000,000 -15,000,000 -31,000,000 -45,000,000 -834,000,000 -336,000,000 -36,000,000 -353,000,000 -207,000,000 -112,000,000 -48,000,000 -44,000,000 -259,000,000 -8,000,000                         
      effect of exchange rates on cash and cash equivalents
    		                        -21,000,000 3,000,000 3,000,000 -12,000,000 -3,000,000 -37,000,000 11,000,000 -7,000,000 25,000,000 6,000,000 28,000,000 -49,000,000 8,000,000 -3,000,000 11,000,000 -131,000,000 14,000,000 -3,000,000 25,000,000 28,000,000   2,000,000 9,000,000 -8,000,000 14,000,000 10,000,000 -2,000,000 10,000,000 -16,000,000 7,000,000 -4,000,000 -25,000,000 6,000,000 20,000,000 0 30,000,000 -9,000,000 -7,000,000 
      net increase/(decrease) in cash and cash equivalents
    		                        2,085,000,000 21,069,000,000 424,000,000                                     
      cash and cash equivalents at beginning of period
    		                        0 0 6,911,000,000  0 0 5,421,000,000  0 0 4,237,000,000  0 0 2,385,000,000  0 0 5,571,000,000  0 0 3,586,000,000  0 0 1,656,000,000  0 0 5,776,000,000  0 0 5,033,000,000  0 0 7,683,000,000 
      cash and cash equivalents at end of period
    		                        2,085,000,000 21,069,000,000 7,335,000,000  409,000,000 -343,000,000 5,342,000,000  1,174,000,000 -440,000,000 3,910,000,000  498,000,000 290,000,000 2,644,000,000  -224,000,000 -2,095,000,000 6,294,000,000  569,000,000 -943,000,000 5,225,000,000  -50,000,000 466,000,000 1,355,000,000  -1,298,000,000 494,000,000 2,307,000,000  806,000,000 260,000,000 3,405,000,000  1,663,000,000 783,000,000 5,135,000,000 
      loss/(gain) on equity investments
    		                           268,000,000 -97,000,000                                   
      increase in cash and cash equivalents
    		                                      259,000,000    723,000,000  569,000,000                   
      cash and cash equivalents at beginning of year
    		                                                               
      cash and cash equivalents at end of year
    		                                                               
      net (decrease)/increase in cash and cash equivalents
    		                                                               
      decrease in cash and cash equivalents
    		                             -343,000,000 -79,000,000                    -301,000,000          1,663,000,000 783,000,000 -2,548,000,000 
      increase/(decrease) in cash and cash equivalents
    		                                 -440,000,000 -327,000,000 805,000,000 498,000,000   -1,590,000,000 -224,000,000      1,639,000,000 1,815,000,000 -50,000,000               
      adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
    		                                                               
      short-term borrowings
    		                                  192,000,000 23,000,000 85,000,000 50,000,000 -33,000,000 -503,000,000 -113,000,000 427,000,000 -260,000,000                     
      interest rate swap contract terminations
    		                                   0 0 0 42,000,000 0 0 -29,000,000 27,000,000 109,000,000 0 0 -4,000,000                 
      issuance of common stock
    		                                   37,000,000 12,000,000 61,000,000 71,000,000          40,000,000 173,000,000 270,000,000             
      adjustments to reconcile net earnings to net cash (used in)/provided by operating activities:
    		                                                               
      net cash (used in)/provided by operating activities
    		                                      -386,000,000                         
      net earnings attributable to noncontrolling interest
    		                                       -9,000,000 -24,000,000   -14,000,000    -9,000,000 0 6,000,000 -14,000,000 1,000,000 2,000,000 -163,000,000 -381,000,000 -379,000,000 -386,000,000 -405,000,000 -381,000,000 -359,000,000 -353,000,000 -341,000,000 -358,000,000 
      other changes
    		                                        305,000,000                       
      purchases of marketable securities
    		                                        -811,000,000 -651,000,000 -821,000,000 -908,000,000 -1,803,000,000 -1,928,000,000 -1,080,000,000 -411,000,000 -598,000,000 -572,000,000 -278,000,000 -106,000,000 -75,000,000 -811,000,000 -2,615,000,000 -1,475,000,000 -1,157,000,000 -1,953,000,000 -2,234,000,000 -2,120,000,000 -116,000,000 -707,000,000 -2,880,000,000 
      additions to property, plant and equipment and capitalized software
    		                                        -234,000,000 -165,000,000 -136,000,000 -191,000,000 -107,000,000 -110,000,000 -118,000,000 -200,000,000 -124,000,000 -98,000,000 -115,000,000 -175,000,000 -137,000,000 -113,000,000 -123,000,000 -134,000,000 -84,000,000 -74,000,000 -75,000,000 -125,000,000 -89,000,000 -81,000,000 -129,000,000 
      divestitures and other proceeds
    		                                        379,000,000                       
      acquisitions and other payments
    		                                        -37,000,000                       
      issuances of common stock
    		                                        30,000,000 27,000,000 174,000,000 59,000,000 29,000,000 28,000,000 172,000,000         236,000,000 130,000,000       
      net (earnings)/loss attributable to noncontrolling interest
    		                                          -13,000,000    1,000,000                 
      gain on sale of businesses and other
    		                                          -234,000,000 -7,000,000                    
      proceeds from sale and maturities of marketable securities
    		                                          1,508,000,000 1,324,000,000 1,833,000,000 562,000,000 376,000,000    551,000,000       1,687,000,000 758,000,000 585,000,000 1,131,000,000   
      business divestitures and other proceeds
    		                                          203,000,000                     
      business acquisitions and other payments
    		                                                               
      proceeds from amylin diabetes alliance
    		                                                               
      short-term debt borrowings
    		                                           199,000,000 40,000,000 84,000,000 -79,000,000                 
      repurchases of common stock
    		                                                               
      proceeds from sale of businesses
    		                                                               
      other investing activities
    		                                            123,000,000 -139,000,000 -21,000,000                 
      proceeds from sale of business
    		                                             104,000,000 3,055,000,000                 
      proceeds from sale of businesses and other investing activities
    		                                                  3,000,000     2,000,000 25,000,000 8,000,000 114,000,000     
      purchase of businesses, net of cash acquired
    		                                                   0 -5,039,000,000 0 -2,491,000,000         
      short-term debt borrowings/
    		                                                  551,000,000          -49,000,000   
      proceeds from amylin diabetes collaboration
    		                                                               
      sale of businesses and other investing activities
    		                                                5,000,000    1,000,000 3,000,000 12,000,000         
      purchases of businesses, net of cash acquired
    		                                                               
      long-term debt repayments
    		                                                   0 -1,999,000,000 0 -109,000,000 0 0 -24,000,000 -54,000,000     
      interest rate swap terminations
    		                                                   0 0 0 2,000,000 0 207,000,000 85,000,000 4,000,000     
      common stock repurchases
    		                                                -53,000,000 -83,000,000 -297,000,000 -492,000,000 -1,051,000,000 -521,000,000 -339,000,000 -362,000,000 -474,000,000 -237,000,000 -148,000,000 -223,000,000 -188,000,000   
      net change in short-term borrowings
    		                                                               
      u.s. and foreign income taxes payable
    		                                                  77,000,000 -132,000,000 7,000,000 97,000,000 -22,000,000 -114,000,000 97,000,000 -47,000,000 -70,000,000 -49,000,000 8,000,000 -89,000,000 -106,000,000 
      dividends paid
    		                                                  -580,000,000 -561,000,000 -571,000,000 -575,000,000 -579,000,000 -560,000,000 -564,000,000 -565,000,000 -565,000,000 -549,000,000 -550,000,000 -552,000,000 -551,000,000 
      other deferred income
    		                                                   195,000,000            
      deferred income from diabetes collaboration
    		                                                               
      short-term borrowings/
    		                                                    -101,000,000 91,000,000 30,000,000  -3,000,000 52,000,000 18,000,000     
      stock option exercises
    		                                                    83,000,000 155,000,000 159,000,000         
      depreciation
    		                                                     90,000,000 85,000,000 115,000,000 105,000,000 111,000,000 117,000,000 125,000,000 102,000,000 124,000,000 122,000,000 
      amortization
    		                                                     102,000,000 101,000,000 92,000,000 93,000,000 95,000,000 73,000,000 73,000,000 66,000,000 67,000,000 65,000,000 
      deferred income tax expense
    		                                                     -124,000,000 204,000,000 142,000,000 30,000,000 66,000,000 177,000,000     
      stock-based compensation expense
    		                                                     40,000,000 42,000,000 41,000,000 39,000,000 43,000,000 38,000,000     
      (decrease)/increase in cash and cash equivalents
    		                                                     494,000,000 -3,469,000,000  806,000,000 260,000,000 -1,628,000,000     
      gain related to divestitures of discontinued operations
    		                                                               
      mead johnson’s cash at split-off
    		                                                               
      short-term debt repayments
    		                                                               
      long-term debt borrowings
    		                                                           0 0   
      proceeds from mead johnson initial public offering
    		                                                               
      proceeds from sales and maturities of marketable securities
    		                                                               
      purchase of amira pharmaceuticals, inc., net of cash acquired
    		                                                               
      issuances of common stock and excess tax benefits from share-based arrangements
    		                                                          53,000,000 41,000,000 89,000,000 40,000,000 82,000,000 
      acquired in-process research and development
    		                                                               
      gain on sale of imclone shares
    		                                                               
      other gains
    		                                                           2,000,000 -19,000,000 -5,000,000 -10,000,000 
      proceeds from sale of businesses, property, plant and equipment and other investments
    		                                                           10,000,000 22,000,000 -2,000,000 37,000,000 
      proceeds from divestitures of discontinued operations
    		                                                               
      proceeds from sale of imclone shares
    		                                                               
      proceeds from sale and leaseback of properties
    		                                                               
      impairment of manufacturing operations
    		                                                            7,000,000   
      changes in other operating assets and liabilities
    		                                                            322,000,000 -182,000,000 -557,000,000 
      purchase of medarex, inc., net of cash acquired
    		                                                               
      interest rate swap termination
    		                                                            0   
      impairment charge
    		                                                              200,000,000 
      proceeds from sale of marketable securities
    		                                                              453,000,000 
      short-term debt (repayments)/borrowings
    		                                                              -17,000,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.